Vanta BioscienceBOM:540729 +4.98%56 EBITDA Margin % is 106.63% as of Mar. 2026, which is 288% above its 10-year median of 27.48. GuruFocus rates BOM:540729 with a GF Score™ of 56/100 and a GF Value™ of ₹12.07 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 205 Medical Diagnostics & Research companies, Vanta Bioscience ranks better than 99.51% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vanta Bioscience's EBITDA for the
six
months ended in Mar. 2026 was ₹16.15 Mil. Vanta Bioscience's Revenue for the
six
months ended in Mar. 2026 was ₹15.15 Mil. Therefore, Vanta Bioscience's EBITDA margin for the quarter that ended in Mar. 2026 was 106.63%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vanta Bioscience EBITDA Margin % Related Terms
Vanta Bioscience EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540729 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience (BOM:540729) has a EBITDA Margin % of 106.63% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vanta Bioscience and its competitors. This is 288% above median its historical median of 27.48. According to the industry distribution chart, Vanta Bioscience ranks #1 out of 205 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Vanta Bioscience's EBITDA Margin % too high?
Vanta Bioscience's current EBITDA Margin % of 106.63% is 288% above median its 10-year median of 27.48. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Vanta Bioscience's value of 106.63% is 2032.6% above this industry median. Based on the distribution chart, Vanta Bioscience ranks #1 out of 205 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vanta Bioscience has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #1 out of 205 companies for EBITDA Margin %. This places Vanta Bioscience in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Vanta Bioscience's value of 106.63% is 2032.6% above this benchmark. While the company's 10-year median is 27.48 vs. the industry median of 5.00, Vanta Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 205 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanta Bioscience's current EBITDA Margin % of 106.63% is 2032.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vanta Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanta Bioscience's current EBITDA Margin % is 106.63%, which is 288% above median its own 10-year median of 27.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.07, compared to a current price of ₹25.29 — trading 109.5% above its estimated fair value. The current EBITDA Margin % is 106.63%, which is 288% above median its 10-year median of 27.48 and 2032.6% above the Medical Diagnostics & Research industry median of 5.00. Vanta Bioscience's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current EBITDA Margin % is 106.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹25.29 is trading 109.5% above its estimated GF Value™ of ₹12.07.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
EBITDA Margin %: 106.63% (288% above median its 10-year median of 27.48)
GF Value™: ₹12.07 vs. price of ₹25.29 (109.5% above fair value)
Industry Position: 2032.6% above the Medical Diagnostics & Research median (#1 of 205)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
56GF Score
Get the complete analysis for BOM:540729
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
